Just Diagnosed

You are here

Just Diagnosed

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Maintenance Therapy, Adjuvant Therapy, Targeted Therapy, Immunotherapies
Case Based Panel Discussion - Advanced Non Squamous NSCLC, Low PD-L1 No Driver Mutation - Is There a Best Systemic Therapy Option?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Maintenance Therapy, Adjuvant Therapy, Targeted Therapy, Immunotherapies
Case Based Panel Discussion - What is the Optimal Approach for a Fit Patient with Advanced Squamous NSCLC and Low Tumor PD-L1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Immunotherapies, Adjuvant Therapy, 3rd Line and beyond, Targeted Therapy
Case Based Panel Discussion - Choosing Between Targeted Therapy and Immunotherapy in a Patient with an EGFR Mutation and High PDL-1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, General Lung Cancer, Non Small Cell Lung Cancer, Immunotherapies
Case Based Panel Discussion - Metastatic Squamous NSCLC Low Tumor PD-L1 Frail Patient - Treatment?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Aging and Elderly, General Lung Cancer, Non Small Cell Lung Cancer, Tumor Marker Tests, Immunotherapies, Chemotherapy

Articles

Progress in Understanding DNA Changes in Lymphoma
Malignant Hematology Progress in understanding DNA changes in lymphoma has already provided improved and highly sensitive tests for detecting this...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Blood Cancers
Disease Learning:
Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, General Blood Cancer
My Top 10 ASCO 2017 Lung Cancer Presentations
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Non Small Cell Lung Cancer, Small Cell Lung Cancer
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Targeted Therapy, Targeted Therapies – ALK
Translation of Molecular Genetics in Lung Cancer into Treatment Decision
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Molecular Testing, General Lung Cancer
Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
First-line treatment, Targeted Therapy, Chemotherapy, Immunotherapies

Community Forum

Nodule concern
I’m a 40yr old female with a smoking history of 20+ years. I have chronic brown phlegm (for years) with little to no coughing. I had a chest X-ray in...
Cancer Journey:
Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Symptoms
Pure GGO repeat scans
Dear Dr. West and other contributing physicians, I am a now 32 year old male. 2 years ago at 30 years of age in early March 2012 a 4mm pure GGO was...
Cancer Journey:
Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning: